Omnicell (NASDAQ:OMCL) Updates Q4 2024 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its fourth quarter 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.550-0.620 for the period, compared to the consensus earnings per share estimate of 0.470. The company issued revenue guidance of $295.0 million-$305.0 million, compared to the consensus revenue estimate of $287.9 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Omnicell Price Performance

Omnicell stock traded up $0.03 during mid-day trading on Friday, reaching $48.67. The company’s stock had a trading volume of 683,792 shares, compared to its average volume of 528,146. The firm’s fifty day moving average price is $43.26 and its two-hundred day moving average price is $35.17. The company has a quick ratio of 2.22, a current ratio of 1.05 and a debt-to-equity ratio of 0.47. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. The firm’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.29 earnings per share. As a group, equities analysts forecast that Omnicell will post 0.64 earnings per share for the current year.

Wall Street Analyst Weigh In

OMCL has been the subject of several analyst reports. Barclays raised their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday. Bank of America restated a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday. Benchmark restated a “buy” rating and issued a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. JPMorgan Chase & Co. lifted their price target on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Finally, Craig Hallum upped their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $49.14.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.